Hypoparathyroidism secondary prevention
Hypoparathyroidism Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Hypoparathyroidism secondary prevention On the Web |
American Roentgen Ray Society Images of Hypoparathyroidism secondary prevention |
Risk calculators and risk factors for Hypoparathyroidism secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Omodamola Aje B.Sc, M.D. [2]
Overview
There are no established measures for the secondary prevention of [disease name].
OR
Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].
Secondary Prevention
- Effective measures for the secondary prevention of hypoparathyroidism is monitoring patients on conventional tharapy. Monitoring guidelines on conventional therapy include:[1][2]
- Serum calcium (corrected for albumin), phosphorus, and creatinine concentrations should be measured weekly to monthly during dose adjustments, and twice annually once a stable regimen has been reached.
- 24 hour Urinary calcium and urine creatinine should be considered during dose adjustments and should be measured twice annually on a stable regimen to evaluate for renal toxicity.
- Estimated gomerular filtration rate (eGFR) should be monitored yearly or more frequently if the clinical situation is appropriate.
- Other imaging studies and examinations may be done as clinically indicated.
- Renal imaging may be done to rule out nephrolithiasis/nephrocalcinosis.
- Ophthalmological exam may be done to rule out cataracts.
- Central nervous system imaging may be done to rule out basal ganglia and other sites of calcification.
- Bone mineral density may be done to rule out to rule out skeletal abnormalities.
References
- ↑ Brandi ML, Bilezikian JP, Shoback D, Bouillon R, Clarke BL, Thakker RV, Khan AA, Potts JT (2016). "Management of Hypoparathyroidism: Summary Statement and Guidelines". J. Clin. Endocrinol. Metab. 101 (6): 2273–83. doi:10.1210/jc.2015-3907. PMID 26943719.
- ↑ Bilezikian JP, Brandi ML, Cusano NE, Mannstadt M, Rejnmark L, Rizzoli R, Rubin MR, Winer KK, Liberman UA, Potts JT (2016). "Management of Hypoparathyroidism: Present and Future". J. Clin. Endocrinol. Metab. 101 (6): 2313–24. doi:10.1210/jc.2015-3910. PMC 5393596. PMID 26938200.